Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 2
1991 1
1992 1
1994 6
1995 20
1996 2
1997 5
1998 3
1999 11
2000 8
2001 11
2002 16
2003 13
2004 4
2005 10
2006 8
2007 8
2008 17
2009 11
2010 7
2011 5
2012 4
2013 7
2014 8
2015 10
2016 10
2017 14
2018 7
2019 7
2020 16
2021 8
2022 10
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: . Clear all
Page 1
Faropenem medoxomil.
Gettig JP, Crank CW, Philbrick AH. Gettig JP, et al. Ann Pharmacother. 2008 Jan;42(1):80-90. doi: 10.1345/aph.1G232. Epub 2007 Dec 19. Ann Pharmacother. 2008. PMID: 18094341 Review.
OBJECTIVE: To review the literature concerning the in vitro activity, pharmacokinetic properties, in vivo efficacy, and adverse events associated with a new penem antibiotic, faropenem medoxomil. DATA SOURCES: We conducted a search of MEDLINE/PubMed and International Pharm …
OBJECTIVE: To review the literature concerning the in vitro activity, pharmacokinetic properties, in vivo efficacy, and adverse events assoc …
Faropenem medoxomil: A0026, BAY 56-6854, BAY 566854, faropenem daloxate, SUN 208, SUN A0026.
[No authors listed] [No authors listed] Drugs R D. 2008;9(2):115-24. doi: 10.2165/00126839-200809020-00005. Drugs R D. 2008. PMID: 18298129 Review.
Replidyne is developing faropenem medoxomil, the ester-type prodrug of faropenem, for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-ac …
Replidyne is developing faropenem medoxomil, the ester-type prodrug of faropenem, for the treatment of bacterial infections an …
Role of Faropenem in Treatment of Pediatric Infections: The Current State of Knowledge.
Nayak S, Pai U, Birla A. Nayak S, et al. Cureus. 2022 Apr 25;14(4):e24453. doi: 10.7759/cureus.24453. eCollection 2022 Apr. Cureus. 2022. PMID: 35497081 Free PMC article. Review.
Faropenem is stable against beta-lactamase and has a low propensity for bacterial resistance. ...Faropenem also has a favorable safety profile. These activities of the faropenem created the interest of researchers in exploring its use in the treatment of pedi …
Faropenem is stable against beta-lactamase and has a low propensity for bacterial resistance. ...Faropenem also has a favorabl …
Impact of acquired broad-spectrum beta-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam beta-lactamase inhibitors in Escherichia coli.
Le Terrier C, Nordmann P, Bouvier M, Poirel L. Le Terrier C, et al. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5. Antimicrob Agents Chemother. 2023. PMID: 37668385 Free PMC article.
The impact of beta-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in Escherichia coli, alone and in combination with avibactam or taniborbactam beta-lactamase inhibitors. ...
The impact of beta-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem …
A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems.
Gandra S, Takahashi S, Mitrani-Gold FS, Mulgirigama A, Ferrinho DA. Gandra S, et al. JAC Antimicrob Resist. 2022 Dec 22;4(6):dlac125. doi: 10.1093/jacamr/dlac125. eCollection 2022 Dec. JAC Antimicrob Resist. 2022. PMID: 36570688 Free PMC article. Review.
SCOPING REVIEW METHODOLOGY: This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infection treatment and evaluated evidence for faropenem resistance and cross-resistance to carbapenems. ...Faropenem dosing regimen …
SCOPING REVIEW METHODOLOGY: This scoping review investigated the impact of faropenem and other oral penems on Enterobacterales infect …
Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis.
Hadley JA, Tillotson GS, Tosiello R, Echols RM. Hadley JA, et al. Expert Rev Anti Infect Ther. 2006 Dec;4(6):923-37. doi: 10.1586/14787210.4.6.923. Expert Rev Anti Infect Ther. 2006. PMID: 17181408 Review.
Faropenem medoxomil is the first oral penem in a new class of beta-lactam antibiotics. ...One study showed faropenem medoxomil to be superior to cefuroxime axetil. Overall, the safety profile of faropenem medoxomil is similar to that of most comparators. ...
Faropenem medoxomil is the first oral penem in a new class of beta-lactam antibiotics. ...One study showed faropenem medoxomil …
Faropenem-induced urticarial vasculitis.
Bhanja DB, Sil A, Panigrahi A, Chakraborty S, Datta M. Bhanja DB, et al. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):146. doi: 10.25259/IJDVL_1052_19. Indian J Dermatol Venereol Leprol. 2021. PMID: 33580928 Free article. No abstract available.
Redefining penems.
Dalhoff A, Janjic N, Echols R. Dalhoff A, et al. Biochem Pharmacol. 2006 Mar 30;71(7):1085-95. doi: 10.1016/j.bcp.2005.12.003. Epub 2006 Jan 18. Biochem Pharmacol. 2006. PMID: 16413506 Review.
The subclass of carbapenems covers the spectrum of hospital pathogens whereas the subclass of penems covers community pathogens. The only currently available penem, faropenem, has a low propensity for resistance development, beta-lactamase induction and selection of carbap …
The subclass of carbapenems covers the spectrum of hospital pathogens whereas the subclass of penems covers community pathogens. The only cu …
Randomized control study of the use of faropenem for treating patients with pulmonary tuberculosis.
Shangguan Y, Guo W, Feng X, Shi Y, Li X, Pan Z, Hu M, Shi J, Ding C, Xia J, Hu W, Ji Z, Zhao C, Li Y, He Z, Jin L, Tao X, Zhu X, Zhang X, Song Q, Zhu Y, Zheng L, Jin X, Huang S, Jiang L, Wang Y, Wu T, Cao D, Zhang Y, Li L, Xu K. Shangguan Y, et al. Int J Infect Dis. 2023 Jul;132:99-107. doi: 10.1016/j.ijid.2023.04.388. Epub 2023 Apr 15. Int J Infect Dis. 2023. PMID: 37068583 Free article. Clinical Trial.
The faropenem group showed noninferiority to the control group in the 6-month treatment success rates. The faropenem group had significantly fewer adverse events (P <0.01). CONCLUSIONS: Our study proved that oral faropenem regimen can be used for the treat …
The faropenem group showed noninferiority to the control group in the 6-month treatment success rates. The faropenem group had …
Faropenem: review of a new oral penem.
Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Schurek KN, et al. Expert Rev Anti Infect Ther. 2007 Apr;5(2):185-98. doi: 10.1586/14787210.5.2.185. Expert Rev Anti Infect Ther. 2007. PMID: 17402834 Review.
Faropenem medoxomil is a new orally administered penem antibiotic. ...However, the US FDA recently rejected faropenem for all four indications stating that the clinical trials in ABS and AECB should have been performed versus a placebo. ...
Faropenem medoxomil is a new orally administered penem antibiotic. ...However, the US FDA recently rejected faropenem for all …
260 results